Picks (written 2026-06-02)
Two of today's research picks put pressure on levodopa's long-term profile: one finding suggests it may raise iron levels in the substantia nigra, while another maps how its neuropsychiatric effects run on a different clock than its motor effects. Neither is a reason to stop medication, but both give patients and neurologists more precise questions to bring to their next appointment.
Latest research
-
Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease summary
Phase 1/2 human safety data on dopamine gene therapy OXB-102/Axo-Lenti-PD.
-
Levodopa increases substantia nigra iron: implications for Parkinson's disease summary
Levodopa may raise substantia nigra iron, raising ferroptosis concern for long-term users.
-
Neuropsychiatric fluctuations follow distinct levodopa timing from motor ones — actionable for dose discussions.
-
Shotgun Metagenomic Profiling of the Gut Virome in Prodromal and Confirmed Parkinson's Disease
Gut virome signature identified in prodromal and confirmed Parkinson's, advancing biomarker work.
-
Mechanism explaining why exercise improves motor plasticity — supports structured exercise prescriptions.
News, foundations & community
-
Parkinson’s Speech Exercises: JUNE CHALLENGE
June speech exercise challenge from Parkinson Voice Project — ready to start today.
-
Anvisa aprova novo medicamento para tratamento da doença de Parkinson avançada - Ceará Agora
Brazil's Anvisa approves new advanced-Parkinson's therapy — regulatory milestone for affected patients.
-
How does exercise and Parkinson's change how many calories I need a day? #shorts#parkinson#exercise
Practical calorie guidance for patients managing exercise intensity with Parkinson's.